Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Skye Bioscience, Inc. | Director | Common Stock | 8.17M | $49.5M | $6.06 | Sep 13, 2024 | By 5AM Ventures VII, L.P. |
Skye Bioscience, Inc. | Director | Common Stock | 1.68M | $10.2M | $6.06 | Sep 13, 2024 | By 5AM Ventures II, L.P. |
Skye Bioscience, Inc. | Director | Common Stock | 66.3K | $402K | $6.06 | Sep 13, 2024 | By 5AM Co-Investors II, L.P. |
Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 14.6M | Dec 3, 2021 | by 5AM Ventures IV, L.P. | ||
Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 3.37M | Dec 3, 2021 | by 5AM Opportunities I, L.P. | ||
Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 2.63M | Oct 15, 2024 | Indirect | ||
Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 610K | Dec 3, 2021 | by 5AM Co-Investors IV, L.P. | ||
Skye Bioscience, Inc. | Director | Stock Option (Right to Buy) | 70K | Oct 28, 2024 | Direct | ||
Enliven Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 27.6K | Feb 23, 2023 | Direct | ||
Camp4 Therapeutics Corp | Director, 10%+ Owner | Series A Prime Preferred Stock | 0 | Oct 15, 2024 | Indirect | ||
Camp4 Therapeutics Corp | Director, 10%+ Owner | Series B Preferred Stock | 0 | Oct 15, 2024 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SKYE | Skye Bioscience, Inc. | Oct 28, 2024 | 1 | $0 | 4 | Oct 30, 2024 | Director |
CAMP | Camp4 Therapeutics Corp | Oct 15, 2024 | 7 | $10M | 4 | Oct 15, 2024 | Director, 10%+ Owner |
CAMP | Camp4 Therapeutics Corp | Oct 10, 2024 | 0 | $0 | 3 | Oct 10, 2024 | Director, 10%+ Owner |
SKYE | Skye Bioscience, Inc. | Sep 11, 2024 | 6 | -$1.75M | 4 | Sep 13, 2024 | Director, 10%+ Owner |
SKYE | Skye Bioscience, Inc. | Mar 13, 2024 | 1 | $4.5M | 4 | Mar 15, 2024 | Director, 10%+ Owner |
SKYE | Skye Bioscience, Inc. | Feb 29, 2024 | 1 | $0 | 4 | Mar 4, 2024 | Director |
SKYE | Skye Bioscience, Inc. | Jan 31, 2024 | 1 | $12M | 4 | Feb 2, 2024 | Director, 10%+ Owner |
SKYE | Skye Bioscience, Inc. | Nov 6, 2023 | 1 | $0 | 4 | Nov 6, 2023 | Director |
SKYE | Skye Bioscience, Inc. | Aug 25, 2023 | 1 | $0 | 4 | Aug 29, 2023 | Director |
SKYE | Skye Bioscience, Inc. | Aug 18, 2023 | 6 | $8.78M | 4 | Aug 22, 2023 | Director, 10%+ Owner |
SKYE | Skye Bioscience, Inc. | Aug 18, 2023 | 0 | $0 | 3 | Aug 22, 2023 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 2 | $0 | 4 | Feb 27, 2023 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 0 | $0 | 3 | Feb 27, 2023 | Director |
PEARQ | Pear Therapeutics, Inc. | Dec 3, 2021 | 4 | $2M | 4 | Dec 7, 2021 | Director, 10%+ Owner |
PEARQ | Pear Therapeutics, Inc. | Dec 3, 2021 | 0 | $0 | 3 | Dec 7, 2021 | Director, 10%+ Owner |